FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge
The latest: Ascletis Pharma Inc. (1672.HK) announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan ($2.3 million) from an 88 million…
Genuine Biotech Seeks IPO Booster from New Oral Covid Drug
Company hopes China’s approval of its small molecule oral Covid-19 drug will draw investors to its newly filed listing plan Key Takeaways: Genuine Biotech has filed to list in Hong…
FAST NEWS: Kintor Pharma Soars on Good Results for Covid Drug
The latest: Kintor Pharmaceutical Ltd. (9939.HK) on Wednesday announced positive results from a Phase 3 clinical trial for its drug Proxalutamide for the treatment of mild-to-moderate ambulatory Covid-19 patients, saying…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
Horizon’s lead grows in smart driving race with new product rollouts
9660.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
